Oppenheimer Downgrades Biogen (BIIB) to Perform
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $216.78 +1.13%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
After the close, Oppenheimer downgraded Biogen (NASDAQ: BIIB) from Outperform to Perform.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $152.94 yesterday.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $152.94 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB) call put ratio 3.7 calls to 1 put with a focus on September calls
- Goldman Sachs Downgrades Hysan Development Company Limited (14:HK) (HYSNY) to Sell
- Deutsche Bank Downgrades Straumann Holding AG (STMN:SW) (SAUHF) to Hold
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
